| Name | Title | Contact Details |
|---|
Secure Doc Imaging is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As an integrated, not-for-profit organization, CentraCare is working to improve the lives and wellbeing of those living in Central Minnesota. CentraCare provides care through hospitals located in St. Cloud, Long Prairie, Melrose, Monticello, Paynesville and Sauk Centre with more than 25 clinics and specialty centers throughout the region. Additionally, Carris Health, a wholly-owned subsidiary of CentraCare, is comprised of Rice Memorial Hospital in Willmar, Redwood Hospital in Redwood Falls and seven clinics in the Southwest and West Central region of the state. CentraCare – St. Cloud Hospital has been a Magnet-designated hospital since 2004 and repeatedly receives national recognition for its outstanding quality measures. CentraCare provides comprehensive primary through tertiary care, CentraCare also operates numerous specialty services, including the CentraCare Heart & Vascular Center, Coborn Cancer Center and the CentraCare Kidney Program. CentraCare serves all who seek care with compassion, dignity and respect, while seeking to enhance individual and community health. Mission: CentraCare Health works to improve the health of every patient, every day. Vision: CentraCare Health will be the leader in Minnesota for quality, safety, service and value. Core Values: •Patient Centered: Serving patients above all. •Integrity: Adhering to honest and ethical practices. •Collaboration: Working jointly with others to improve health and health care. •Compassion: Serving all who seek our care with kindness, dignity, and respect. •Stewardship: Ensuring responsible use of all resources to best serve our communities.
Highmark Medicare Services Inc is a Camp Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
PayLess Drug Stores is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Portland, OR. To find more information about PayLess Drug Stores, please visit www.paylessdrug.com